A 44-year-old woman with scleroderma-like skin lesions and malignant hypertension following mammoplastyis reported. Sclerotic change is an unusual finding for ordinary finding progressive systemic sclerosis. On admission, she had severe high-renin hypertension and progressive renal failure, suggesting scleroderma renal crisis. With intensive treatment for hypertension including angiotensin-converting enzyme inhibitor, the blood pressure was well controlled. It was then suggested that she had malignant hypertension due to scleroderma after silicone injection, or the so-called humanadjuvant disease after cosmetic surgery.
In 1964, Miyoshi et al reported two patients with undifferentiated connective tissue disease who had undergone augmentation mammoplasty using either paraffin or silicone (1). They suggested that this morbidity was the result of prolonged exposure to the injected substances through the adjuvant effect, as the features were similar to those in adjuvant arthritis in rats treated with paraffin (2, 3). Consequently, it has been referred to as human adjuvant disease. There are more than fifty reported cases presenting with connective tissue diseases after cosmetic surgery (4-9). In these cases, scleroderma was the most characteristic feature. Kumagaiet al reported that 12 out of 46 patients with connective tissue diseases after cosmetic surgery had scleroderma (5). Although patients with progressive systemic sclerosis (PSS) are often complicated with renal involvement and malignant hypertension (scleroderma renal crisis), very few patients with human adjuvant disease are complicated with malignant hypertension (10).
Werecently encountered a patient with malignant hypertension and scleroderma following mammoplasty with direct injection of silicone. This scleroderma renal crisis-like status could be improved by control of the blood pressure with intensive treatment of hypertension.
CASE REPORT
A 44-year-old Japanese womanwas admitted to our hospital because of severe hypertension, general malaise, and blurred vision. There was a history of autoimmunediseases in her family members; her father suffered from rheumatoid arthritis, mother, Hashimoto's disease, and brother, Graves' disease. (Fig. 1) .
The clinical course after admission is shown in Fig. 2 . Because the patient had severe hypertension, Keith-Wegener grade 4 changes in the optic fundi, heart failure and rapidly progressive renal failure, the morbidity was diagnosed as malignant hypertension. We immediately started to treat her with an intensive combination therapy of ACEinhibitor (captopril 50 mg/day), calcium antagonist (nifedipine 60 mg/day) and alpha-receptor blocker (prazosin 1.0 mg/day). Subsequently, ACEinhibitor was changed to enalapril 20 mg/day. Then, the blood pressure responded and was decreased to ACE,angiotensin converting enzyme; BP, blood pressure;
Cr, serum creatinine; PRA, plasma renin activity mmHg but without any improvement in her scleroderma. Serum lactic dehydrogenase and amylase levels were 391 IU/1 and 285 IU/1, respectively. Five months later, she was well on a regimen of lower doses of antihypertensive drugs (enalapril 10 mg/day and nifedipine 20 mg/day) with a blood pressure of 120/80 mmHg and serum creatinine level of 2.5 mg/dl.
DISCUSSION
A patient with human adjuvant disease after mammoplasty, presenting with scleroderma-like skin lesions and malignant hypertension is reported. This patient had scleroderma in the fingers, forearms, anterior chest, and face. It was hidebound and fibrotic, and not atrophic nor edematous. The skin changes were more prominent in the anterior chest than in the extremities. Although patients with diffuse scleroderma can have widespread hidebound skin, the distribution of sclerotic changes in the skin was untypical of PSS. In the serological study, as well, specific markers of PSS such as anti Scl-70 antibody and anticentromere antibody were negative. Since the patient received mammoplasty with silicone injected directly into the breasts 25 yrs ago, the skin lesion is considered to represent scleroderma following cosmetic surgery, a characteristic of the so-called human adjuvant disease (4-9). It is of interest that she had a positive family history of various autoimmune diseases; this genetic trend might have been contributory to the development of her scleroderma following cosmetic surgery.
More than fifty cases of human adjuvant disease presenting with connective tissue diseases after cosmetic surgery have been reported; the most frequent type of the connective tissue disease was scleroderma. The incidence of scleroderma was statistically higher in patients receiving cosmetic surgery, when compared with the expected value for all womenwithout cosmetic surgery. Consequently, the adjuvant effect of silicone has been invoked as the primary factor in the development of scleroderma(5). In some cases scleroderma was improved by removal of the injected material (1 , 1 1). Here no attempt was madeto removethe foreign substance, because it was injected directly into the breasts. The possible sequence of events in this patient is thought to be the following: scleroderma was induced by the adjuvant effect of silicone used at mammoplasty,resulting in the development of malignant hypertension possibly by narrowing the lumen of renal arterioles. In addition, strain and dehydration served as aggravating factors.
There are very few cases of malignant hypertension and scleroderma following cosmetic surgery (10), although patients with PSS often have malignant hypertension, "scleroderma renal crisis" (12, 13) . The present patient seems to be in a scleroderma renal crisis-like status, because she had sclerodermatous skin lesions and severe high-renin hypertension with progressive renal failure. Her condition vertually fulfilled the diagnostic criterion for scleroderma renal crisis advocated by Traub et al (12) or Steen et al (13). Since neither renal biopsy nor renal artery angiography was performed because of severe renal failure and extremely high blood pressure, we were not able to clarify precisely whether or not this was in scleroderma renal crisis. Based on the increased serum lactic dehydro-genase level on admission, it can not be attributed to microangiopathic hemolytic anemia which is the commoncharacteristic of malignant hypertension, since she had a normal serum bilirubin level and no red cell fragmentation. However, we should consider the involvement of some organs due to the extremely high blood pressure since the serum lactic dehydrogenase level was normalized after the reduction of blood pressure. Furthermore, it should be noted that the serum amylase level on admission was markedly increased. The pancreas is one of the organs most commonly affected with the necrotizing lesions of malignant hypertension (14, 15). The serum concentration of amylase gradually decreased with normalization of blood pressure but the level was still slightly high, possibly due to renal insufficiency. 
Letters to the Editor
Dihydroergotamine raises the level of serum growth hormone To the editor: A patient with a high serum growth hormone(GH) level which seemed to be induced by dihydroergotamine (DHE) is described. DHE acts as a partial alpha-adrenergic agonist as well as a central alpha-adrenergic antagonist (1). It has been widely used to treat migraine and orthostatic hypotension. A central alpha-adrenergic agonist is known as a factor of increasing GHsecretion. However, it has not been reported that DHEraises the level of GH.
Report of a case -A 30-year-old male was referred to our hospital because of orthostatic hypotension. The DHE had been administered for about 3 yr. Because he was tall on examination, we measured serum GHlevel, which showed high serum level (15.0 ng/ml; N< 5.0 ng/ml). However, brain computed tomographic scan could not detect the pituitary tumor or other brain disease. In addition, the level of GH decreased from 17 ng/ml to 0.3 ng/ml after administration of75 g glucose, which is known as one of the screening tests for acromegaly (2). The serum GHlevel returned to normal level within 2 days after administration of DHEwas discontinued. Therefore, we suspected that DHEraised the serum GHlevel. To confirm this GHraising effect, we made a DHEloading test. The serum was taken before and after taking 1 mg of DHE. The GH level increased like this: 0' 0.9 ng/ml, 30' 0.6 ng/ml, 60' 1.9 ng/ml, 90' 17.0 ng/ml, 120' 14.0 ng/ml, 150' ll ng/ml, 180' 3.5 ng/ml. Serum levels of glucose and fatty acids were not changed. From these results, it is clear that DHEaffected the serum GH level in our patient. been used as a disease modifying anti-rheumatic drug in Japan since 1987. This is the first report concerning the possible association of this drug and MG. The patient was a 36-year-old female with an 8-yr history ofRA. From January 21, 1988, she had received D-PC (100 mg/day), and her rheumatic symptomsimproved. However, because of the side effect of decreased serum immunoglobulin A, D-PC was discontinued on April 4, 1988. From May 12, 1988, she was given 100 mg/day of bucillamine, and her rheumatic symptomsimproved; she received this medication every 2 days from September 1, 1988. In July 1989, she started to feel weakness of extremities. After about 2 wk, she had diplopia, blepharoptosis and weakness of upper limbs which worsened in the evening. She decided to stop taking bucillamine on August 2, 1989 and was admitted to our hospital three days later. She was diagnosed to have MG, based on the clinical symptoms, a 15%decrement in response to repetitive nerve stimulation on the hypothenar muscle, positive tensilone tests, and high levels of serum antiacetylcholine receptor (Ach R) antibodies (89 nmol/1: N < 0.5 nmol/1). Hyperplasia of the thymus was detected on magnetic resonance imaging. Her myasthenic symptomswere improved slightly after discontinuation of bucillamine but she required pyridostigmine bromide (120 mg/day) treatment. Since
October 5, 1989, she has undergone plasmapheresis using an IM-T35O immunoabsorbent column 6 times. She showed complete disappearance of myasthenic symptoms after plasmapheresis, and did not need anticholinergic drugs. However she showed myasthenic symptoms again after discharge. So she was treated again by plasmapheresis, steroid pulse therapy and an immunosuppressive agent (Azathioprine).
Her clinical symptoms improved but her symptoms and high level of anti-AchR antibody were still present.
It can be suggested that the MGin this patient was associated with the bucillamine treatment, because of the clinical course; the onset of MGoccurred during the treatment with bucillamine, and slight, transient improvement of symptoms wasseen after discontinuation of the drug.
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